Zolmitriptan for acute migraine attacks in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2014, Pages

  Bird, Sarah ^a   Derry, Sheena ^b   Moore, R Andrew ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; KETOPROFEN; METOCLOPRAMIDE; NARATRIPTAN; NOSE SPRAY; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TELCAGEPANT; ZOLMITRIPTAN; OXAZOLIDINONE DERIVATIVE; SEROTONIN 1 AGONIST; TRYPTAMINE DERIVATIVE;

ADULT; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; MIGRAINE; NUMBER NEEDED TO HARM; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PAIN SEVERITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TABLET; UNSPECIFIED SIDE EFFECT; ACUTE PAIN; META ANALYSIS; MIGRAINE DISORDERS; ORAL DRUG ADMINISTRATION; TIME;

ACUTE PAIN; ADMINISTRATION, ORAL; ADULT; HUMANS; MIGRAINE DISORDERS; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TIME FACTORS; TRYPTAMINES;

EID: 84922520111     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008616.pub2     Document Type: Review

References (87)

1. Astra Zeneca. A multicentre, randomised, double-blind trial to compare the efficacy and safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and placebo in the acute treatment of adult patients with migraine. www.astrazenecaclinicaltrials.com 2005. 3161923
2. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003;17(9):653-67. 3161925
3. Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, et al. Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eurean Journal of Neurology 1998;5(6):535-43. 3161927
4. Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG, Bi-Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 2002;58(11):1660-5. 3161929
5. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 2005;19(2):125-36. 3161931
6. Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002;22(2):101-6. 3161933
7. Gallagher RM, Dennish G, Spierings EL, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 2000;45(1):7-16. 3161935
8. Gawel M, Aschoff J, May A, Charlesworth BR, REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study. Headache 2005;45(1):7-16. 3161937
9. Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC, et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 2000;20(1):30-8. 3161939
10. Geraud G, Compagnon A, Rossi A, COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. European Neurology 2002;47(2):88-98. 3161941
11. Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurological Sciences 2006;27 Suppl 2:S193-7. [DOI: 10.1007/s10072-006-0600-4]3161943
12. Goadsby PJ, Massiou H, Pascual J, Diener HC, Dahlöf CG, Mateos V. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurologica Scandinavica 2007;115(1):34-40. 3161944
13. Gruffyd-Jones K, Kies B, Middleton A, Mulder LJ, Røsjø Ø, Millson DS. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. European Journal of Neurology 2001;8(3):237-45. 3161946
14. Dodick DW, Kost J, Assaid C, Lines C, Ho TW. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia 2011;31(3):296-300. [DOI: 10.1177/0333102410385585]3161948
15. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372(9656):2115-23. 3161949
16. Klapper J, Lucas C, Røsjø Ø, Charlesworth B, ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004;24(11):918-24. 3161951
17. Loder E, Freitag FG, Adelman J, Pearlmand S, Abu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial. Current Medical Research and Opinion 2005;21(3):381-9. 3161953
18. Pascual J, Vega P, Diener HC, Allen C, Vrijens F, Patel K. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000;20(5):455-61. 3161955
19. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997;49(5):1210-8. 3161957
20. Ryan RE, Diamond S, Giammarco RAM, Aurora SK, Reed RC, Fletcher PE. Efficacy of zolmitriptan at early time-points for the acute treatment of migraine and treatment recurrence. A randomised, placebo-controlled trial. CNS Drugs 2000;13(3):215-26. 3161959
21. Sakai F, Iwata M, Tashiro K, Itoyama Y, Tsuji S, Fukuuchi Y, et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study. Cephalalgia 2002;22(5):376-83. 3161961
22. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology 1997;49(5):1219-25. 3161963
23. Spierings EL, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs 2004;18(15):1133-41. 3161965
24. Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003;23(10):942-52. 3161967
25. Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs 2006;20(12):1019-26. 3161969
26. Allais G, Tullo V, Benedetto C, Zava D, Omboni S, Bussone G. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurological Sciences 2011;32 Suppl 1:S99-104. [DOI: 10.1007/s10072-011-0547-y]3161971
27. Tullo V, Allais G, Curone M, Ferrari MD, Omboni S, Benedetto C, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double-blind, randomized, multicenter, Italian study. Neurological Sciences 2012;33 Suppl 1:S61-4. [DOI: 10.1007/s10072-012-1043-8]3161972
28. Tullo V, Allais G, Ferrari MD, Curone M, Mea E, Omboni S, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurological Sciences 2010;31 Suppl 1:S51-4. 3161973
29. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996;46(2):522-6. 3161975
30. Dowson AJ, Charlesworth BR, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 2003;17(11):839-51. 3161977
31. Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004;44(2):120-30. 3161979
32. Mauskop A, Farkkila M, Hering-Hanit R, Rapoport A, Warner J. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. Current Medical Research and Opinion 1999;15(4):282-9. 3161981
33. Tepper SJ, Donnan GA, Dowson AJ, Bomhof MA, Elkind A, Meloche J, et al. A long-term study to maximise migraine relief with zolmitriptan. Current Medical Research and Opinion 1999;15(4):254-71. 3161983
34. Dr Avanti Biniwale (Principle investigator). A Clinical Trial to evaluate efficacy and safety of zolmitriptan 5 mg nasal spray in acute treatment of migraine. http://ctri.nic.in (accessed 13 November 2013) 2013. [CTRI/2009/091/000196]3161985
35. Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009;146(3):261-9. [DOI: 10.1016/j.pain.2009.07.010]
36. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia 2012;32(5):373-81. [DOI: 10.1177/0333102412438977]
37. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559-66. [DOI: 10.1212/01.wnl.0000323925.29520.e7]
38. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain 2012;13(5):361-78. [DOI: 10.1007/s10194-012-0460-7]
39. Zolmitriptan. British National Formulary 2013; Vol. March:Available at http://www.medicinescomplete.com/mc/bnf/current/PHP2859-zolmitriptan.htm.
40. Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 2012;52(1):3-17. [DOI: 10.1111/j.1526-4610.2011.02046.x]
41. Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 2008;48(2):236-47. [DOI: 10.1111/j.1526-4610.2007.01007.x]
42. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997;72(1-2):95-7.
43. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452-4.
44. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008615.pub2]
45. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009665]
46. Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009663]
47. Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009664]
48. Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008040.pub3]
49. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-63. [DOI: 10.1111/j.1526-4610.2006.00631.x]
50. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [DOI: 10.1093/ije/31.1.140]
51. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22(8):633-58. [DOI: 10.1046/j.1468-2982.2002.00404.x]
52. Gendolla A. Early treatment in migraine: how strong is the current evidence?. Cephalalgia 2008;28 Suppl 2:28-35. [DOI: 10.1111/j.1468-2982.2008.01688.x]
53. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends in Molecular Medicine 2007;13(1):39-44. [DOI: 10.1016/j.molmed.2006.11.005]
54. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health 2009;12(1):55-64. [DOI: 10.1111/j.1524-4733.2008.00404.x]
55. Higgins JPT, Green S (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
56. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96.
57. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20(9):765-86.
58. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):1-160.
59. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629-808. [DOI: 10.1177/0333102413485658]
60. Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain 1996;66(2-3):239-46.
61. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
62. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine 1996;156(6):661-6.
63. Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008041.pub3]
64. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107(2):224-33.
65. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). Journal of Headache and Pain 2005;6(6):429-40. [DOI: 10.1007/s10194-005-0252-4]
66. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology 2012;19(5):703-11. [DOI: 10.1111/j.1468-1331.2011.03612.x]
67. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache 1999;39(Suppl 2):S20-S26.
68. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, AMPP Advisory Group, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-9.
69. Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006;46(5):715-25. [DOI: 10.1111/j.1526-4610.2006.00430.x]
70. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16.
71. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
72. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. ''Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150:386-389.
73. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with confidence - confidence intervals and statistical guidelines. London: British Medical Journal, 1995:50-63.
74. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009;49(4):498-508. [DOI: 10.1111/j.1526-4610.2009.01369.x]
75. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97(3):247-57. [DOI: 10.1016/S0304-3959(02)00024-6]
76. Anonymous. Prescription cost analysis, England 2011. The NHS Information Centre, Prescribing Support Unit 2012. [ISBN: 978-1-84636-685-7]
77. Rabbie R, Derry S, Moore RA, McQuay HJ. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008039.pub3]
78. Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. Headache 2009;49(1):79-89. [DOI: 10.1111/j.1526-4610.2008.01263.x]
79. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
80. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326(7387):472. [DOI: 10.1136/bmj.326.7387.472]
81. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Journal of Headache and Pain 2013;14:1. [DOI: 10.1186/1129-2377-14-1]
82. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain 2010;11(4):289-99. [DOI: 10.1007/s10194-010-0217-0]
83. Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia 2013;Oct 9 [epub]. [DOI: 10.1177/0333102413508661]
84. Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate results on meta-analysis: a case study. BMJ 1997;315(7109):635-40.
85. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30(9):1065-72.
86. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 1016/S0140-6736(12)61729-2]
87. Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache 2012;52(4):582-91. [DOI: 10.1111/j.1526-4610.2011.02061.x]